Mark Sumeray has 23 years of experience across the pharmaceutical, medical devices and biotech industries, both in the US and EU. Prior to Amolyt, he spent six years as chief medical officer at Amryt Pharmaceuticals, where he was responsible for development, regulatory and safety areas of the company. He was closely involved in support for the approval and launch of new treatments for patients with acromegaly, lipodystrophy, epidermolysis bullosa and homozygous familial hypercholesterolemia and led the clinical and scientific interactions with global health authorities. Prior to Amryt, he spent five years as chief medical officer at Aegerion Pharmaceuticals. Earlier in his career he worked at Bristol-Myers Squibb, where he led a large US medical affairs team within the cardiovascular and metabolics area. He also previously worked at Ethicon, a Johnson & Johnson medical device company, where he was responsible for the clinical group. He spent nine years in clinical practice in the NHS, specializing in cardiovascular surgery and physiology. Mark received his bachelor’s and M.D. from University College London and FRCS qualification from Royal College of Surgeons.